Raymond James & Associates’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $55.9K | Sell |
42,311
-8,928
| -17% | -$11.8K | ﹤0.01% | 3797 |
|
|
2024
Q2 | $52.3K | Buy |
51,239
+10,000
| +24% | +$10.2K | ﹤0.01% | 3748 |
|
|
2024
Q1 | $75.5K | Buy |
41,239
+11,322
| +38% | +$20.7K | ﹤0.01% | 3728 |
|
|
2023
Q4 | $37.1K | Buy |
29,917
+9,696
| +48% | +$12K | ﹤0.01% | 3685 |
|
|
2023
Q3 | $23.1K | Buy |
20,221
+8,619
| +74% | +$9.83K | ﹤0.01% | 3686 |
|
|
2023
Q2 | $10.6K | Buy |
+11,602
| New | +$10.6K | ﹤0.01% | 3749 |
|
|
2022
Q3 | – | Sell |
-12,900
| Closed | -$5K | – | 3793 |
|
|
2022
Q2 | $5K | Hold |
12,900
| – | – | ﹤0.01% | 3838 |
|
|
2022
Q1 | $9K | Sell |
12,900
-10,500
| -45% | -$7.33K | ﹤0.01% | 3923 |
|
|
2021
Q4 | $53K | Buy |
23,400
+1,005
| +4% | +$2.28K | ﹤0.01% | 3871 |
|
|
2021
Q3 | $64K | Hold |
22,395
| – | – | ﹤0.01% | 3835 |
|
|
2021
Q2 | $85K | Buy |
22,395
+224
| +1% | +$850 | ﹤0.01% | 3803 |
|
|
2021
Q1 | $75K | Buy |
22,171
+1,800
| +9% | +$6.09K | ﹤0.01% | 3744 |
|
|
2020
Q4 | $57K | Buy |
20,371
+9,750
| +92% | +$27.3K | ﹤0.01% | 3551 |
|
|
2020
Q3 | $27K | Sell |
10,621
-4,645
| -30% | -$11.8K | ﹤0.01% | 3419 |
|
|
2020
Q2 | $207K | Buy |
15,266
+1,331
| +10% | +$18K | ﹤0.01% | 3092 |
|
|
2020
Q1 | $106K | Sell |
13,935
-2,374
| -15% | -$18.1K | ﹤0.01% | 3180 |
|
|
2019
Q4 | $103K | Sell |
16,309
-5,043
| -24% | -$31.8K | ﹤0.01% | 3429 |
|
|
2019
Q3 | $84K | Buy |
21,352
+1,852
| +9% | +$7.29K | ﹤0.01% | 3370 |
|
|
2019
Q2 | $94K | Buy |
+19,500
| New | +$94K | ﹤0.01% | 3372 |
|
|
2018
Q3 | – | Sell |
-38,698
| Closed | -$386K | – | 3496 |
|
|
2018
Q2 | $386K | Sell |
38,698
-63
| -0.2% | -$628 | ﹤0.01% | 2844 |
|
|
2018
Q1 | $369K | Sell |
38,761
-798
| -2% | -$7.6K | ﹤0.01% | 2749 |
|
|
2017
Q4 | $588K | Buy |
39,559
+2,721
| +7% | +$40.4K | ﹤0.01% | 2423 |
|
|
2017
Q3 | $725K | Buy |
36,838
+321
| +0.9% | +$6.32K | ﹤0.01% | 2273 |
|
|
2017
Q2 | $525K | Buy |
36,517
+519
| +1% | +$7.46K | ﹤0.01% | 2377 |
|
|
2017
Q1 | $331K | Buy |
35,998
+2,184
| +6% | +$20.1K | ﹤0.01% | 2622 |
|
|
2016
Q4 | $352K | Buy |
33,814
+5,068
| +18% | +$52.8K | ﹤0.01% | 2532 |
|
|
2016
Q3 | $260K | Buy |
28,746
+5,809
| +25% | +$52.5K | ﹤0.01% | 2694 |
|
|
2016
Q2 | $172K | Sell |
22,937
-228
| -1% | -$1.71K | ﹤0.01% | 2688 |
|
|
2016
Q1 | $209K | Sell |
23,165
-764
| -3% | -$6.89K | ﹤0.01% | 2545 |
|
|
2015
Q4 | $309K | Buy |
+23,929
| New | +$309K | ﹤0.01% | 2178 |
|